Table 2.
Differentially expressed proteins identified using SWATH MS analysis of MDA-MB-231 cell lysate and secretome following adrenoceptor agonism/antagonism.
| Lysate | Secretome | |||||
|---|---|---|---|---|---|---|
| Treatment (vs UT) | Protein | Swiss-Prot ID | Log2 Fold Change | Protein | Swiss-Prot ID | Log2 Fold Change |
| NE | No significantly changed proteins | STC1 | P52823 | 1.385 | ||
| PPI1A | P62937 | 1.106 | ||||
| CSF1 | P09603 | −1.025 | ||||
| B2MG | P61769 | −1.145 | ||||
| LFNG | Q8NES3 | −1.146 | ||||
| PTX3 | P26022 | −1.151 | ||||
| CUL5 | Q93034 | −1.160 | ||||
| HUWE1 | Q7Z6Z7 | −1.172 | ||||
| ANR28 | O15084 | −1.226 | ||||
| UROK | P00749 | −1.364 | ||||
| ITIH2 | P19823 | −1.383 | ||||
| CTGF | P29279 | −1.443 | ||||
| TSP1 | P07996 | −1.461 | ||||
| KI13B | Q9NQT8 | −2.489 | ||||
| ISO | G45IP | Q8TAE8 | 3.552 | STC1 | P52823 | 1.097 |
| ODBA | P12694 | 3.331 | KI13B | Q9NQT8 | −1.048 | |
| BAF | O75531 | −1.013 | PPT1 | P50897 | −1.062 | |
| DBNL | Q9UJU6 | −1.025 | CAD11 | P55287 | −1.088 | |
| S10A4 | P26447 | −1.037 | CSF1 | P09603 | −1.109 | |
| THIO | P10599 | −1.074 | HUWE1 | Q7Z6Z7 | −1.164 | |
| NEDD8 | Q15843 | −1.117 | TSP1 | P07996 | −1.219 | |
| ANXA2 | P07355 | −1.129 | CTGF | P29279 | −1.446 | |
| CYTB | P04080 | −1.171 | UROK | P00749 | −1.564 | |
| PEBP1 | P30086 | −1.240 | CATD | P07339 | −2.309 | |
| PRDX3 | P30048 | −1.273 | ANR28 | O15084 | −2.313 | |
| LEG1 | P09382 | −1.329 | ||||
| GLRX3 | O76003 | −1.526 | ||||
| ANXA5 | P08758 | −2.254 | ||||
| TGM2 | P21980 | −4.288 | ||||
| ICI 118,551 | GLSK | O94925 | 1.757 | HUWE1 | Q7Z6Z7 | −1.053 |
| 2A5E | Q16537 | 1.179 | ANR28 | O15084 | −1.581 | |
| LEG1 | P09382 | −1.017 | ||||
| PRDX3 | P30048 | −1.027 | ||||
| ANX11 | P50995 | −1.097 | ||||
| OST48 | P39656 | −1.141 | ||||
| ANXA2 | P07355 | −1.491 | ||||
| CALX | P27824 | −1.565 | ||||
| S10AA | P60903 | −1.615 | ||||
| ANXA4 | P09525 | −1.670 | ||||
| PEBP1 | P30086 | −1.788 | ||||
| GALT2 | Q10471 | −1.927 | ||||
| DNJA2 | O60884 | −2.297 | ||||
| CP1B1 | Q16678 | −3.311 | ||||
| ICI 118,551 + NE | ODBA | P12694 | 3.341 | RLA2 | P62805 | 1.019 |
| S10AA | P60903 | −1.077 | CUL5 | Q93034 | −1.049 | |
| ANX11 | P50995 | −1.223 | H4 | P62805 | −1.071 | |
| ANXA2 | P07355 | −1.460 | TCRG1 | O14776 | −1.078 | |
| ANXA4 | P09525 | −1.779 | BGH3 | Q15582 | −1.079 | |
| CP013 | Q96S19 | −2.699 | PPT1 | P50897 | −1.175 | |
| CYTS | P01037 | −1.180 | ||||
| TSP1 | P07996 | −1.230 | ||||
| CYTN | P01037 | −1.298 | ||||
| SRPX | P78539 | −1.345 | ||||
| HUWE1 | Q7Z6Z7 | −1.454 | ||||
| ITIH2 | P19823 | −1.509 | ||||
| FINC | P02751 | −1.510 | ||||
| ANR28 | O15084 | −1.930 | ||||
| KI13B | Q9NQT8 | −2.080 | ||||
Log2 fold change represents the increase/decrease in protein expression relative to untreated samples (UT). Proteins with a Log2 fold change of <1.0 or >1.0 and OneOmics confidence of ≥60% are shown. Proteins with single peptides are excluded. Data is from six biological replicates. NE—norepinephrine, ISO—isoproterenol, UT—untreated.